HIV Infections
📧 Sign up to get email alerts when something new happens for HIV Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-29Clinical Trial Update: Optimizing CAB-LA as PrEP for Women Who Inject Drugs
Clinical trial update reporting the completion of a study optimizing cabotegravir long-acting as pre-exposure prophylaxis for women who inje…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants [Phase 1]
This Phase 1 study evaluates the pharmacokinetics, safety and tolerability of a long-acting cabotegravir formulation administered with recom…
-
EMA approval · 2025-12-11EMA Authorised: Pifeltro (doravirine) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Pifeltro (doravirine) for HIV infections, marking EU marketing authorization for this antiretrovira…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV [Phase 1]
This update outlines a Phase 1 study to evaluate tolerability and acceptability of long-acting cabotegravir and lenacapavir injections in he…
-
EMA approval · 2025-11-18EMA Authorised: Truvada (emtricitabine;tenofovir disoproxil fumarate) — Gilead Sciences Ireland UC
The EMA has authorized Truvada (emtricitabine; tenofovir disoproxil fumarate) for use in HIV infections. MAH is Gilead Sciences Ireland UC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-14EMA Authorised: Tivicay (dolutegravir) — ViiV Healthcare BV
EMA has authorised Tivicay (dolutegravir) for HIV infections, confirming regulatory approval in the European Union.
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) [Phase 2]
Phase 2 trial assessing safety and immunogenicity of the MVA-based CMV vaccine Triplex has completed.
-
EMA approval · 2025-11-04EMA Authorised: Rekambys (rilpivirine) — Janssen-Cilag International NV
EMA authorised Rekambys (rilpivirine) by Janssen-Cilag International NV for HIV infections.
-
EMA approval · 2025-10-30EMA Authorised: Vocabria (cabotegavir sodium;cabotegravir) — ViiV Healthcare B.V.
EU medicines authority authorised Vocabria (cabotegravir) for HIV infections; marketing authorisation holder is ViiV Healthcare B.V.; decisi…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Consent for Use of Stored Patient Specimens for Future Testing
This clinical trial update explains consent terms for using stored patient specimens for future testing in an HIV/AIDS study sponsored by Ad…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Optimizing Care for Challenging People Living With HIV [NA]
This clinical trial update notes that the study optimizing care for people living with HIV is currently enrolling by invitation, focusing on…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults [Phase 1]
Phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of a single-dose suspension injection of investigational capsid inh…
-
CLINICAL_TRIALS withdrawal · 2025-08-17Clinical Trial Update: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa [Phase 1, Phase 2]
The Phase 1/2 trial evaluating safety and immunogenicity of VPM1002 vaccination or BCG revaccination for tuberculosis in HIV-infected and un…
-
CLINICAL_TRIALS other · 2025-08-17Clinical Trial Update: Mindfulness Intervention for Individuals With HIV and Chronic Pain [NA]
A clinical trial evaluating a mindfulness intervention for people with HIV and chronic pain is currently suspended, according to ClinicalTri…
-
EMA approval · 2025-08-04EMA Authorised: Rezolsta (darunavir;cobicistat) — Janssen-Cilag International N.V.
EMA authorised Rezolsta (darunavir/cobicistat) for HIV infections, a fixed-dose combination co-formulated by Janssen-Cilag International N.V…
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT [Phase 2]
A Phase 2 clinical trial is evaluating how microbiome metabolites and alcohol influence cardiovascular risk in people with HIV; recruitment …
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years. [EARLY_Phase 1]
A Phase 1 study evaluating the safety and immunogenicity of an HIV-1 vaccine regimen (UVAX-1107 with adjuvant, followed by UVAX-1107 or UVAX…
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals [Phase 1]
This is a Phase 1 clinical trial evaluating HIV-1 specific T cells (HST-NEETs) in HIV-infected individuals. The study status indicates the t…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE [Phase 3]
Phase 3 trial update on a long-acting therapy for HIV infections; status ACTIVE_NOT_RECRUITING with results posted in 2025.
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Buprenorphine Integration Research and Community Health [NA]
Clinical trial update on buprenorphine integration research and community health, sponsored by Yale University, investigating opioid use dis…
-
EMA approval · 2025-04-11EMA Authorised: Edurant (rilpivirine hydrochloride) — Janssen-Cilag International N.V.
The EMA authorised Edurant (rilpivirine hydrochloride) for HIV infections. Decision date: 11 April 2025.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya [Phase 1]
Phase 1 trial completed evaluating safety and immune response of Env-C DNA and Env-C protein vaccines in adults with HIV infections in Kenya…
-
EMA approval · 2025-03-19EMA Authorised: Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine;tenofovir disoproxil phosphate) — Zentiva k.s.
EMA authorised Emtricitabine/Tenofovir disoproxil Zentiva for HIV infections; a fixed-dose combination antiretroviral therapy.
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Neuropathy Walks (Cross-sectional)
A completed cross-sectional clinical trial update studying neuropathy in people with HIV infections, sponsored by Rutgers.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) [Phase 1]
Phase 1 study evaluating Tc-99m tilmanocept given intravenously and subcutaneously in Kaposi sarcoma patients (including individuals with HI…